{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa%2C+Dystrophic&page=2",
    "query": {
      "condition": "Epidermolysis Bullosa, Dystrophic",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 53,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa%2C+Dystrophic&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa%2C+Dystrophic&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T02:57:25.568Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00587223",
      "title": "Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa, Junctional",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "Apligraf",
          "type": "DEVICE"
        },
        {
          "name": "Standard dressing regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Organogenesis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-12",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2010-06-29",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Miami, Florida • New York, New York + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587223"
    },
    {
      "nct_id": "NCT05843994",
      "title": "Artificial Intelligence Patient App for RDEB SCCs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "online survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-01-30",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05843994"
    },
    {
      "nct_id": "NCT04214002",
      "title": "The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa",
        "DEB - Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-01",
      "completion_date": "2020-02-24",
      "has_results": false,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214002"
    },
    {
      "nct_id": "NCT06892639",
      "title": "Evaluation of D-Fi for the Treatment of Wounds Due to DEB",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "D-Fi",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Castle Creek Biosciences, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2025-03-27",
      "completion_date": "2042-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 4,
      "location_summary": "Redwood City, California • Santa Margarita, California • Aurora, Colorado + 1 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Santa Margarita",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06892639"
    },
    {
      "nct_id": "NCT04213261",
      "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "FCX-007 (dabocemagene autoficel; see below for FCX-007 description)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Castle Creek Biosciences, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-06-09",
      "completion_date": "2037-07",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213261"
    },
    {
      "nct_id": "NCT01768026",
      "title": "Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lotus Tissue Repair, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2013-02",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2013-05-21",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768026"
    },
    {
      "nct_id": "NCT01538862",
      "title": "Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Granulocyte Colony Stimulating Factor (GCSF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2012-02",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-23",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01538862"
    },
    {
      "nct_id": "NCT02670330",
      "title": "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101-6.0 cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 152,
      "start_date": "2015-06-09",
      "completion_date": "2018-09-03",
      "has_results": true,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670330"
    },
    {
      "nct_id": "NCT03012191",
      "title": "Gentamicin for RDEB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recessive Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Gentamicin Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 6,
      "start_date": "2017-02-02",
      "completion_date": "2018-08-31",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012191"
    },
    {
      "nct_id": "NCT00881556",
      "title": "Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Palifermin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Lorazepam",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 3,
      "start_date": "2009-08-20",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-10-10T02:57:25.568Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Chicago, Illinois • New York, New York",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00881556"
    }
  ]
}